T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
NCT ID: NCT02457650
Last Updated: 2016-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
36 participants
INTERVENTIONAL
2015-04-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies. The patients pretreated with a lymphodepleting preconditioning regimen will be monitored after infusion of anti-NY-ESO-1 TCR-transduced T cells for adverse events, persistence of anti-NY-ESO-1 TCR-transduced T cells and treatment efficacy.
Objectives:
To evaluate the safety and the efficacy of anti-NY-ESO-1 TCR-transduced T cell-based immunotherapy for patients with NY-ESO-1- expressing malignancies.
Eligibility:
Patients older than one year of age, who have relapsed or refractory malignancies that express both NY-ESO-1 and human leukocyte antigen (HLA)-A2 molecules.
Patients must have adequate organ functions.
Design:
* Peripheral blood from patients will be collected for isolation of peripheral blood mononuclear cells (PBMCs), which will be transduced with a lentiviral or retroviral vector encoding an HLA-A2 restricted anti-NY-ESO-1 TCR gene.
* Patients will receive a lymphodepleting preconditioning regimen to prepare their immune system to accept modified T cells.
* Patients will receive an infusion of their own modified T cells. They will remain in the hospital to be monitored for adverse events until they have recovered from the treatment.
* Patients will have frequent follow-up visits to monitor the persistence of modified T cells and efficacy of the treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
NCT01967823
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
NCT05296564
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
NCT02775292
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
NCT02062359
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
NCT01457131
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this trial, autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies after they receive a lymphodepleting preconditioning regimen. The patients will be monitored after infusion of anti-NY-ESO-1 TCR-transduced T cells for adverse events, persistence of anti-NY-ESO-1 TCR-transduced T cells and treatment efficacy.
Primary objectives:
To determine the safety and feasibility of the administration of anti-NY-ESO-1 TCR transduced T cells in patients with HLA-A2+ NY-ESO-1-expressing malignancies.
Secondary objectives:
To determine if the treatment can result in clinical regression of malignant tumors in the patients.
To determine the in vivo persistency of the anti-NY-ESO-1 TCR-transduced T cells.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anti-NY ESO-1 TCR-transduced T cells
Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.
Cyclophosphamide
On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
Fludarabine
On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
Anti-NY ESO-1 TCR-transduced T cells
Modified cells will be infused IV over 30 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
Fludarabine
On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
Anti-NY ESO-1 TCR-transduced T cells
Modified cells will be infused IV over 30 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must be HLA-A2 positive, and cancer tissues express NY-ESO-1；
3. There is at least one measurable disease: diameter ≥20mm or spiral CT≥10mm；
4. Willing to sign a durable power of attorney；
5. Able to understand and sign the Informed Consent Document；
6. Performance status：ECOG 0-2；
7. Life expectancy：More than 3 months；
8. Patients must be willing to practice birth control for four months after receiving a lymphodepleting preconditioning regimen；
9. Patients with no pregnancy and lactation；
10. Hematopoietic： (1) Absolute neutrophil count \> 1000/mm3 without support of filgrastim； (2) Platelet count \> 100,000/mm3； (3) Hemoglobin \> 8.0 g/dL； (4) lymphocyte count \>500/mm3； (5) WBC \> 3,000/mm3；
11. Chemistry： (1) AST and ALT \< 2.5 times upper limit of normal； (2) Serum creatinine≤1.6 mg/dl； (3) Bilirubin ≤1.5 mg/dL（3.0 mg/dL in patients with Gilbert's syndrome）；
12. Seronegative for hepatitis B and C viruses；
13. Seronegative for human immunodeficiency virus (HIV) antibody；
14. More than four weeks must have elapsed since any prior systemic therapy at the time of randomization, and patients' toxicities must have recovered to a grade 1 or less (except for alopecia or vitiligo). Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteria；
15. Six weeks must have elapsed since any prior anti-CTLA4 antibody therapy to allow antibody levels to decline. Patients who have previously received any anti-CTLA4 antibody and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies.
Exclusion Criteria
2. Active systemic infections；
3. Coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system；
4. Concurrent use of systemic steroids；
5. History of severe immediate hypersensitivity reaction to any of the agents used in this study；
6. There are obvious dysfunctions in heart , liver，kidney and other vital organs
7. T cell lymphoma and leukemia patients；
8. HIV positive；
9. History of coronary revascularization or ischemic symptoms；
10. Documented Left Ventricular Ejection Fraction (LVEF) of less than or equal to 45 percent tested in patients with: Clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block；
11. Documented forced expiratory volume 1 (FEV1) less than or equal to 60 percent predicted tested in patients with a prolonged history of cigarette smoking (20 pk/yrs of smoking) or symptoms of respiratory dysfunction；
12. Bronchial lesions (probably shifted obstructive pneumonia or intracranial hemorrhage risk)
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen Institute for Innovation and Translational Medicine
OTHER
Shenzhen Second People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201504002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.